Why the study?
The study evaluated the efficacy, safety, and characteristics of patients who respond well to standard-dose triple combination therapy with telmisartan, amlodipine, and chlorthalidone in hypertensive patients.
Does triple combination therapy of telmisartan, amlodipine, and chlorthalidone reduce mean sitting systolic blood pressure compared to dual therapy in patients with primary hypertension?
Population
374 hypertensive patients
Comparison
Triple combination (telmisartan/amlodipine/chlorthalidone) vs dual combination (telmisartan/amlodipine)
Design
Multicenter, double-blind, active-controlled, phase 3 randomized trial
Follow-up
8 weeks
Key result
Triple combination therapy with telmisartan/amlodipine/chlorthalidone significantly reduced mean sitting systolic blood pressure compared to dual therapy (-19.1 vs -11.4 mm Hg; p<0.0001).
Authors
Loading...
Supports triple combination therapy in primary hypertension; confirms superiority over dual regimens in randomized evidence.
RCT (n=374)
Double-blind
randomized
Yes
Does triple combination therapy of telmisartan, amlodipine, and chlorthalidone reduce mean sitting systolic blood pressure compared to dual therapy in patients with primary hypertension?
Absolute Event Rate: -19.1% vs -11.4%
p-value: p=< .0001
A standard dose triple combination of telmisartan, amlodipine, and chlorthalidone is highly efficacious and safe for lowering blood pressure in primary hypertension compared to dual therapy.
Cho et al. (2023) conducted an RCT in primary hypertension (n=374). telmisartan/amlodipine/chlorthalidone vs. telmisartan/amlodipine (80 mg/5 mg) was evaluated on change of mean sitting systolic blood pressure (MSSBP) at week 8 (p=< .0001). Triple combination therapy with telmisartan/amlodipine/chlorthalidone significantly reduced mean sitting systolic blood pressure compared to dual therapy (-19.1 vs -11.4 mm Hg; p<0.0001).